Abstract:Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatments. Here we describe a novel CLL cell line (OSU-CLL) generated by EBV transformation, which displays a similar cytogenetic and immunophenotype observed in the patient’s CLL (CD5 positive with trisomy 12 and 19). A companion cell line was also generated from the sam… Show more
“…This cell line has the immunophenotype and migratory properties similar to the primary CLL tumor from which it was derived. 19 In this system, based on the engraftment of 5 to 10 million B-CLL cells, neither single-agent ibrutinib nor CTL019 affected overall survival. In contrast, the combination of these agents resulted in both markedly enhanced CTL019 engraftment in the peripheral blood ( Figure 6G) and significant prolongation of survival ( Figure 6H).…”
Section: Org Frommentioning
confidence: 87%
“…19 Wild-type parental K562 cells (purchased from American Type Culture Collection), K562 cells engineered to express CD19 (K562-CD19) along with PD-L1 (K562-CD19-PDL1), and Nalm-6 cells (American Type Culture Collection) were used as targets where indicated in the relevant experiments. Primary donor T cells were transduced with the anti-CD19 CAR containing a 4-1BB intracellular signaling domain (CTL019) and expanded as previously reported.…”
Section: Cell Lines Dna Constructs and Generation Of Ctl019 Cellsmentioning
Key Points
Ibrutinib treatment of CLL enhances the generation of CAR T cells for adoptive immunotherapy. Concurrent ibrutinib therapy improves the engraftment and therapeutic efficacy of anti-CD19 CAR T cells in mouse models.
“…This cell line has the immunophenotype and migratory properties similar to the primary CLL tumor from which it was derived. 19 In this system, based on the engraftment of 5 to 10 million B-CLL cells, neither single-agent ibrutinib nor CTL019 affected overall survival. In contrast, the combination of these agents resulted in both markedly enhanced CTL019 engraftment in the peripheral blood ( Figure 6G) and significant prolongation of survival ( Figure 6H).…”
Section: Org Frommentioning
confidence: 87%
“…19 Wild-type parental K562 cells (purchased from American Type Culture Collection), K562 cells engineered to express CD19 (K562-CD19) along with PD-L1 (K562-CD19-PDL1), and Nalm-6 cells (American Type Culture Collection) were used as targets where indicated in the relevant experiments. Primary donor T cells were transduced with the anti-CD19 CAR containing a 4-1BB intracellular signaling domain (CTL019) and expanded as previously reported.…”
Section: Cell Lines Dna Constructs and Generation Of Ctl019 Cellsmentioning
Key Points
Ibrutinib treatment of CLL enhances the generation of CAR T cells for adoptive immunotherapy. Concurrent ibrutinib therapy improves the engraftment and therapeutic efficacy of anti-CD19 CAR T cells in mouse models.
“…10 The retroviral construct pRetroX-Tight-Puro was used to stably transfect XLA cells with BTK. A mutation was made using QuikChange site directed mutagenesis (Stratagene) in the kinase domain at cysteine 481 to serine (see the primer sequence in supplemental Methods on the Blood Web site).…”
Section: Retroviral Vectors and Generations Of Btk Cell Linesmentioning
“…29 This cell line displays immunophenotype and cytogenetics similar to the patient's CLL (trisomy 12 and 19). OSUCLL cells with doxycycline-inducible expression of normal or mutated BRAF were previously described.…”
Key Points• Mutated BRAF accelerates disease and enhances immune abnormalities in murine B-cell leukemia.• This new model will be valuable for understanding and targeting disease-induced immune modulation in MAPK-mutated B-cell malignancies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.